Citations (14)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Giacomo Casalini, Andrea Giacomelli & Spinello Antinori. (2022) Liver tests abnormalities with licensed antiviral drugs for COVID-19: a narrative review. Expert Opinion on Drug Safety 21:12, pages 1483-1494.
Read now
Read now
Mona Arab-Alameddine, Laurent Arhtur Décosterd, Thierry Buclin, Amalio Telenti & Chantal Csajka. (2011) Antiretroviral drug toxicity in relation to pharmacokinetics, metabolic profile and pharmacogenetics. Expert Opinion on Drug Metabolism & Toxicology 7:5, pages 609-622.
Read now
Read now
Articles from other publishers (12)
Xuechun Mu, Yujiao Duan, Qiuhua Xu, Sa Wang, Guiju Gao, Ning Han & Hongxin Zhao. (2023) Torsade de pointes associated with long-term antiretroviral drugs in a patient with HIV: a case report. Frontiers in Pharmacology 14.
Crossref
Crossref
Wei Zhang, Lili Lin, Wanjin Fu, Dandan Bao, Qian Zhang, Yueyue Liu, Liang Zheng & Wei Hu. (2023) Pharmacokinetics, Safety, and Bioequivalence of 2 Lopinavir/Ritonavir (200/50 mg) Tablets in Healthy Chinese Volunteers: Effect of Food on Absorption. Clinical Pharmacology in Drug Development 12:6, pages 602-610.
Crossref
Crossref
Taťána Majerová & Jan Konvalinka. (2022) Viral proteases as therapeutic targets. Molecular Aspects of Medicine 88, pages 101159.
Crossref
Crossref
A. Yu. Sambyalova, T. A. Bairova, T. L. Manaenkova & L. V. Rychkova. (2021) The role of pharmacogenetics in Efficacy and safety of protease inhibitor based therapy in human immunodeficiency virus type (HIV) infection.. Acta Biomedica Scientifica 6:6-2, pages 113-124.
Crossref
Crossref
Ekhlass Uddin, Raisul Islam, Ashrafuzzaman, Nur Amin Bitu, Md. Saddam Hossain, ABM Nazmul Islam, Ali Asraf, Faruk Hossen, Ranjan K Mohapatra & Md. Kudrat-E-Zahan. (2021) Potential Drugs for the Treatment of COVID-19: Synthesis, Brief History and Application. Current Drug Research Reviews 13:3, pages 184-202.
Crossref
Crossref
Noam Ben-Zuk, Ido-David Dechtman, Itai Henn, Libby Weiss, Amichay Afriat, Esther Krasner & Yoav Gal. (2021) Potential Prophylactic Treatments for COVID-19. Viruses 13:7, pages 1292.
Crossref
Crossref
Benjamin Batteux, Sandra Bodeau, Valérie Gras‐Champel, Sophie Liabeuf, Jean‐Philippe Lanoix, Jean‐Luc Schmit, Claire Andréjak, Yoann Zerbib, Guillaume Haye, Kamel Masmoudi, Anne‐Sophie Lemaire‐Hurtel & Youssef Bennis. (2020) Abnormal laboratory findings and plasma concentration monitoring of lopinavir and ritonavir in COVID‐19. British Journal of Clinical Pharmacology 87:3, pages 1547-1553.
Crossref
Crossref
Xiaoli Du, Wenxiu Peng, Qiang Fu, Qing Ma, Zhu Zhu & Taisheng Li. (2019) A Review of Clinical Pharmacokinetic and Pharmacodynamic Profiles of Select Antiretrovirals: Focus on Differences among Chinese Patients. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 39:12, pages 1179-1189.
Crossref
Crossref
Sarmad Waqas & John S Lambert. (2015) Therapeutic drug monitoring in HIV-infected pregnant women with a focus on protease inhibitors. Future Virology 10:7, pages 915-922.
Crossref
Crossref
Nils Von Hentig, Errol Babacan, Schlomo Staszewski, Martin Stürmer, Hans W Doerr & Jörn Lötsch. (2007) Predictive Factors for Response to a Boosted Dual HIV-Protease Inhibitor Therapy with Saquinavir and Lopinavir in Extensively Pre-Treated Patients. Antiviral Therapy 12:8, pages 1237-1246.
Crossref
Crossref
M.T.M. Roberts & S.H. Aliyu. (2007) Hyponatraemia associated with lopinavir–ritonavir?. International Journal of Infectious Diseases 11:1, pages 83-84.
Crossref
Crossref
Roberto Manfredi & Sergio Sabbatani. (2006) Serious, multi-organ hypersensitivity to lopinavir alone, involving cutaneous-mucous rash, and myeloid, liver, and kidney function. AIDS 20:18, pages 2399-2400.
Crossref
Crossref